Chromatographic Profiling and Cytotoxic studies of Extracts of Buchanania lanzan Spreng and Albizia lebbeck Benth

• Published in: Research journal of pharmacy and technology 2024-01, Vol.17 (1), p.103-108
• Main Authors: Shrivastava, Jyoti, Madhuri, T. Ratna, Shah, Abhishek
• Format: Article
• Language: English
• Subjects: Acids; Ayurvedic medicine; Cancer therapies; Chromatography; Cytotoxicity; Drugs; Flavonoids; Medical research; Phenols; Phytochemicals; Traditions
• ISSN: 0974-3618; 0974-360X; 0974-306X
• DOI: 10.52711/0974-360X.2024.00016

The various Indian systems of medicine in addition to numerous local health traditions have been successful in managing cancer across the globe using herbs. Keeping all this in mind, the present study has been taken up, to study the cytotoxic potential of B.lanzan and A.lebbeck barks. The objective of the present study is to explore the scientific basis of both plant bark for its anti-carcinogenic utility. Different extracts of plants were screened using the MTT assay technique, and potent extracts were subjected to HPTLC and HPLC to evaluate total phenolic and flavonoid present in crude extracts of plant bark. In our study, we found that the ethanolic fraction of B. lanzan had higher phenolic content 34.92 µg/mL than other fractions. While in the case of flavonoids ethyl acetate fraction of A.lebbeck contain the highest concentration 17.00 µg/mL. In the MTT assay, B. lanzan ethyl acetate extract (B-EA), ethanolic extract of B. lanzan (BE) and A. lebbeck ethyl acetate extract (L-EA) had shown an IC50 value of 113.9 µg/mL, 247.4µg/mL, 152.7µg/mL, while in A549 cells, B-EA, BE, L-EA had shown 226.9µg/mL, 269.1µg/mL, 123.3µg/mL IC50 values respectively. The effect of samples B-EA, and L-EA was found different in HeLa cell lines from the other two studies. The samples B-EA and L-EA showed the value of 91.9µg/mL and 257.1µg/mL, respectively. A. lebbeck ethanol extract (LA) did not show significant inhibition in HepG2, A549, and HeLa cells, and sample BE did not show substantial inhibition in HeLa cells. B.lanzan and A. lebbeck have a high potency to treat liver, lung and cervical cancers in vitro, although extensive pharmacological and clinical studies are required to explore inherent mechanisms in future.